CORCEPT THERAPEUTICS INC — Director's Dealing 2021

Sep 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CORCEPT THERAPEUTICS INC (CORT)
CIK: 0001088856
Period of Report: 2021-09-01

Reporting Person: Maduck Sean (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-01	Common Stock	M	25000	$3.29	Acquired	65024	Direct
2021-09-01	Common Stock	S	25000	$21.3972	Disposed	40024	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-01	Stock Option (Right to Buy)	$3.29	M	25000	Disposed	2025-02-18	Common Stock (25000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	10000	Indirect
Common Stock	10000	Indirect

Footnotes

F1: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.

F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $21.38 to $21.445 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

F3: Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

F4: Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee.

F5: Fully exercisable.